Zelira Therapeutics Ltd
ZLD
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
8
Stocks News & Analysis
stocks
Hostile takeover on the cards for this ASX income opportunity
IFM lobs reasonable takeover offer.
stocks
Get ready for major US tech earnings starting tomorrow morning
Microsoft, Amazon, Alphabet, and Meta will all release quarterly earnings. Here’s what analysts are looking for.
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.70 | 16.00 | 0.18% |
| CAC 40 | 8,072.13 | 31.96 | -0.39% |
| DAX 40 | 23,954.56 | 63.70 | -0.27% |
| Dow JONES (US) | 48,777.34 | 364.59 | -0.74% |
| FTSE 100 | 10,213.11 | 119.68 | -1.16% |
| HKSE | 26,111.84 | 432.06 | 1.68% |
| NASDAQ | 24,613.95 | 49.85 | -0.20% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,770.30 | 5.90 | 0.05% |
| S&P 500 | 7,119.24 | 19.56 | -0.27% |
| S&P/ASX 200 | 8,687.00 | 9.40 | 0.11% |
| SSE Composite Index | 4,107.51 | 28.88 | 0.71% |